This interaction is problematic for two reasons: (1) inhibition of OATP1B1 increases plasma concentrations of statins resulting in an increased risk for statin-related myopathies; (2) inhibition of OATP1B1 reduces efficacy of statins since functional OATP1B1 transporters are required for statin transport to hepatocytes (the site of action for statins). This evidence concerns the gene SLCO1B1 and myopathy.